HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael C Carroll Selected Research

Complement C4 (Complement Component 4)

1/2022Author Correction: Schizophrenia risk from complex variation of complement component 4.
1/2021Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice.
2/2016Schizophrenia risk from complex variation of complement component 4.
12/2007Reduced tissue damage and improved recovery of motor function after traumatic brain injury in mice deficient in complement component C4.
9/2002Anti-DNA autoreactivity in C4-deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael C Carroll Research Topics

Disease

15Reperfusion Injury
01/2016 - 11/2002
10Inflammation (Inflammations)
01/2017 - 04/2003
8Ischemia
08/2009 - 08/2004
7Infections
11/2019 - 05/2002
6Systemic Lupus Erythematosus (Libman-Sacks Disease)
11/2020 - 02/2002
6Human Influenza (Influenza)
11/2019 - 04/2007
5Schizophrenia (Dementia Praecox)
01/2022 - 02/2016
5Neoplasms (Cancer)
01/2019 - 01/2017
4Autoimmune Diseases (Autoimmune Disease)
11/2021 - 01/2017
4Myocardial Infarction
01/2016 - 06/2005
3Myocardial Ischemia (Ischemic Heart Diseases)
01/2016 - 07/2006
3Arthritis (Polyarthritis)
09/2007 - 02/2002
3Wounds and Injuries (Trauma)
03/2007 - 06/2005
2Infarction (Infarctions)
01/2016 - 09/2010
2Alzheimer Disease (Alzheimer's Disease)
05/2012 - 06/2008
2Traumatic Brain Injuries (Traumatic Brain Injury)
05/2008 - 12/2007
1Graft vs Host Disease (Graft-Versus-Host Disease)
01/2019
1Breast Neoplasms (Breast Cancer)
12/2018
1Lymphatic Metastasis
01/2018
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2018
1Carcinoma (Carcinomatosis)
01/2018
1Melanoma (Melanoma, Malignant)
01/2018
1Neurodevelopmental Disorders
01/2017
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2017
1Necrosis
01/2017
1Autistic Disorder (Autism)
01/2017
1Cytokine Release Syndrome
01/2017
1Hypoxia (Hypoxemia)
01/2016
1Left Ventricular Dysfunction
01/2016
1Agammaglobulinemia (Hypogammaglobulinemia)
07/2012
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
07/2012
1Acute-Phase Reaction
04/2012
1Tertiary Lymphoid Structures
12/2011
1Amyloid Plaque
06/2008
1Viral Pneumonia
04/2007
1Burns
03/2007
1Polyomavirus Infections
08/2006
1Myocardial Reperfusion Injury
07/2006
1Hyperplasia
05/2006

Drug/Important Bio-Agent (IBA)

20Complement System Proteins (Complement)IBA
05/2017 - 05/2002
14Immunoglobulin M (IgM)IBA
01/2016 - 11/2002
7Proteins (Proteins, Gene)FDA Link
12/2018 - 01/2005
5Complement C4 (Complement Component 4)IBA
01/2022 - 09/2002
5AutoantibodiesIBA
11/2021 - 09/2007
4LectinsIBA
01/2020 - 08/2006
4Immunoglobulins (Immunoglobulin)IBA
01/2019 - 02/2002
4Mannose-Binding Lectin (Mannan-Binding Lectin)IBA
09/2010 - 10/2006
3Influenza Vaccines (Influenza Vaccine)FDA Link
01/2019 - 09/2010
3Peptides (Polypeptides)IBA
05/2017 - 02/2006
3AntibodiesIBA
05/2017 - 02/2006
3AntigensIBA
05/2017 - 02/2006
3Monoclonal AntibodiesIBA
01/2016 - 05/2002
3AutoantigensIBA
09/2010 - 01/2006
3Complement C3 (C3 Complement)IBA
05/2006 - 02/2002
2EpitopesIBA
01/2019 - 08/2017
2Complement Receptors (Complement Receptor)IBA
01/2017 - 08/2006
2CytokinesIBA
05/2013 - 12/2011
2Peptide Hydrolases (Proteases)FDA Link
12/2012 - 06/2005
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2008 - 11/2003
2Immunoglobulin G (IgG)IBA
08/2006 - 05/2002
1Complement C4aIBA
01/2021
1Protein Isoforms (Isoforms)IBA
01/2020
1Interferon Type IIBA
11/2019
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
11/2019
1C-Type Lectins (C-Type Lectin)IBA
11/2019
1Hemagglutinins (Hemagglutinin)IBA
01/2019
1OvalbuminIBA
01/2019
1RNA (Ribonucleic Acid)IBA
01/2019
1Complementarity Determining Regions (Complementarity Determining Region)IBA
01/2019
1micaIBA
01/2019
1Complement 3d Receptors (Complement Receptor 2)IBA
05/2017
1Programmed Cell Death 1 ReceptorIBA
05/2017
1InflammasomesIBA
01/2017
1Toll-Like Receptor 7IBA
01/2017
1EmulsionsIBA
01/2017
1MF59 oil emulsionIBA
01/2017
1VaccinesIBA
01/2017
1TroponinIBA
01/2016
1Myosin Heavy Chains (Myosin Heavy Chain)IBA
01/2016
1Troponin T (Troponin T1)IBA
01/2016
1von Willebrand FactorIBA
12/2012
1Signaling Lymphocytic Activation Molecule Associated ProteinIBA
07/2012
1Amyloid (Amyloid Fibrils)IBA
05/2012
1ChemokinesIBA
04/2012
1Interleukin-17 (Interleukin 17)IBA
12/2011
1Troponin IIBA
09/2010
1salicylhydroxamic acid (SHAM)IBA
08/2009
1Nuclear Proteins (Protein, Nuclear)IBA
06/2008
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
06/2008
1InterleukinsIBA
06/2008
1dimemorfan (AT 17)IBA
06/2008
1Viral ProteinsIBA
08/2006
1Collagen Type II (Type II Collagen)IBA
08/2006
1CollagenIBA
08/2006
1Messenger RNA (mRNA)IBA
08/2006
1Complement Factor B (Factor B)IBA
05/2006
1AllergensIBA
05/2006
1Interleukin-4 (Interleukin 4)IBA
05/2006

Therapy/Procedure

2Therapeutics
01/2018 - 01/2016
1Immunotherapy
12/2018